Why It’s Lights Out for Orexigen Therapeutics, Inc. | Traderszone

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 12 May, 2015 by The TZ Newswire Staff

Why It’s Lights Out for Orexigen Therapeutics, Inc.

Orexigen Therapeutics shares tumble after the company announces the termination of a critical post-marketing approval study for Contrave.

See also
- Next Article Why Treasury yields could be topping
- Previous Article Capitol Report: Obama’s trade agenda dealt setback after Senate Democrats revolt
Editorial Calender

May 2015

M T W T F S S

1 2 3

4 5 6 7 8 9 10

11 12 13 14 15 16 17

18 19 20 21 22 23 24

25 26 27 28 29 30 31

« Apr Jun »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar